Lexaria Secures IP Milestones, Opens Talks with Multinationals on Oral GLP-1 Platform
Lexaria achieved key IP milestones in 2024–25 for its DehydraTECH oral GLP-1 platform and is in early-stage discussions with multinational pharmaceutical companies on potential commercial partnerships. The global GLP-1 market is projected to reach $126 billion by 2029 and $180 billion by 2035, fueled by blockbusters and rising oral drug demand.
1. DehydraTECH Platform Advancements
The company completed proprietary formulation improvements and secured new intellectual property for its oral GLP-1 delivery platform in 2024 and 2025, aiming to enhance tolerability and efficacy in capsule and tablet forms.
2. Early-Stage Pharmaceutical Discussions
Management is engaged in preliminary discussions with several multinational pharmaceutical firms to explore licensing or co-development agreements for its oral GLP-1 candidate, leveraging growing industry interest in non-injectable therapies.
3. Market Opportunity Analysis
Global sales of GLP-1 drugs are forecast to reach $126 billion by 2029 and $180 billion by 2035, driven by top-selling therapies and significant patient demand for oral alternatives that could reduce high rates of gastrointestinal side effects.
4. Competitive Landscape and Next Steps
While blockbuster injectables currently dominate, multiple oral GLP-1 candidates are under development across the industry; the company plans further platform enhancements to position its candidate for Phase II and III studies and attract commercial partners.